Prytime Medical's pREBOA-PRO™ Catheter Launches in Europe

Prytime Medical's Launch of the pREBOA-PRO™ Catheter in Europe

Prytime Medical, known as The REBOA Company™, recently made headlines with the announcement of their pREBOA-PRO™ catheter's first civilian implementation in a European healthcare setting. This transformative device marks a significant advancement in the medical field, particularly in the management of life-threatening hemorrhaging.

Understanding the pREBOA-PRO™ Catheter

The pREBOA-PRO™ catheter stands out as the world’s first device crafted specifically for prolonged aortic occlusion. This unique technology enhances resuscitative endovascular balloon occlusion of the aorta (REBOA) procedures. Unlike its predecessors, which limited occlusion times to about 30 minutes, the pREBOA-PRO™ catheter allows clinicians to extend the safe occlusion period to a remarkable 2 hours. This innovative capability could dramatically alter the treatment approach for critically injured patients, yielding better patient outcomes.

Contribution to Trauma Care

This catheter represents a critical tool for health professionals dealing with situations that involve severe bleeding. By allowing controlled resuscitation during emergencies, the device aids in stabilizing patients who are at a severe risk of hemorrhagic shock.

First Civilian Use in Europe

Dr. Tal Hörer, an Associate Professor of Surgery at Örebro University Hospital, was the pioneer in utilizing the pREBOA-PRO™ catheter for a patient experiencing acute post-partum hemorrhaging. His positive assessment of the device highlights its role in trauma care: "The pREBOA-PRO™ catheter illustrates a leap forward in REBOA technology, maximizing our flexibility to treat critically injured patients efficiently. It helps us avoid ischemic complications that can occur when total aortic occlusion is utilized. This device has significantly bolstered our trauma care toolkit."

CEO Insights on Expanding Access

David Spencer, the CEO of Prytime Medical, expressed his enthusiasm about the CE Mark approval, stating, "This milestone is vital for our objective to broaden the availability of life-saving REBOA technology. The pREBOA-PRO™ catheter will empower medical teams within Europe to address non-compressible torso hemorrhages with greater efficacy, thereby preserving more lives."

Proven Effectiveness and Global Rollout Plan

With more than 700 successful deployments across various U.S. medical facilities, the pREBOA-PRO™ catheter equips physicians with the necessary time for thorough patient evaluation and stabilization. Notably, it achieves this without amplifying the risk of acute kidney injury (AKI).

Prytime Medical has plans to strategically introduce the pREBOA-PRO™ catheter into select European markets throughout the upcoming year.

About Prytime Medical

Prytime Medical Devices, Inc. is dedicated to innovative solutions in the realm of resuscitative endovascular balloon occlusion of the aorta (REBOA). The company focuses on improving results for patients during critical care scenarios by offering advanced technologies aimed at managing hemorrhagic shock efficiently.

Frequently Asked Questions

What is the pREBOA-PRO™ catheter?

The pREBOA-PRO™ catheter is a device designed for prolonged aortic occlusion to manage severe hemorrhaging in trauma patients.

How does the pREBOA-PRO™ catheter enhance treatment effectiveness?

This catheter allows for safe aortic occlusion for up to 2 hours, surpassing the previous 30-minute limit, thereby improving patient management.

Who conducted the first civilian use of the catheter in Europe?

Dr. Tal Hörer at Örebro University Hospital performed the first European application of the pREBOA-PRO™ catheter.

What are the expected benefits of using this catheter?

The expected benefits include improved flexibility in treating severely injured patients and reducing complications associated with traditional total occlusion methods.

When will the catheter be available in Europe?

Prytime Medical plans to roll out the pREBOA-PRO™ catheter in select European markets starting in the upcoming year.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.